REMARKS

Currently claims 1 through 44 are pending. Claims 3, 4, 7, 8, 9, 11, 13, 15, 16, 17, 19, 20, 21, 22, 23, 30 and 31 have been amended in order to reduce the filing fee by removing multiple dependencies and/or to correct typographical errors.

The specification has been amended to include a reference to related applications/claim of priority to the corresponding PCT application and foreign filed application.

Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

Applicants respectfully submit that the present application is in condition for examination and respectfully request the early consideration thereof and the issuance of a Notice of Allowance forthwith.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted:

Gussler

Frank P. Grassler

Attorney for Applicants

Reg. No. 31,164

Date: <u>Juy 28, 2006</u> GlaxoSmithKline Inc. Corporate Intellectual Property Five Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709

Tel. (919) 483-9024 Fax: (919) 483-7988 Application No. PCT/EP2005/000841 Attorney Docket No. PLP573

Amendments to the Abstract:

Please substitute the attached Abstract, which has been placed on a separate sheet of paper according to US practice, as required under 37 CFR 1.72(b).